Exclusive Baidu Geely Joint Voice: The transfer process has been completed, and the social security for employees of Jiyue was paid in November. On the afternoon of December 13th, Sina Technology learned exclusively that Baidu and Geely Automobile, the two major shareholders of Jiyue Automobile, have reached a consensus today and jointly stated that as shareholders, they will actively assist the management of Jiyue to properly handle related matters: the social security payment for employees and the compensation for employees who leave their posts will be solved as soon as possible; Maintain the normal use, after-sales and maintenance of users' vehicles; Promote the reasonable and legal settlement of other matters. According to reports, Geely and Baidu have completed the transfer process on the evening of the 12th, and paid social security for the employees in November. It is reported that Jidu Automobile Co., Ltd. is a new start-up company established by Geely Holding and Baidu Holding, and it is an innovative product to explore the intelligent transformation of automobiles. Jiyue automobile products are manufactured by Geely factory and authorized to operate exclusively by Jidu. Due to the great changes in the industry competition pattern, the established business plan cannot be implemented and the operation has encountered challenges. (Sina Technology)Before the US stock market: China ETF-Direxion fell by nearly 4% and Broadcom rose by about 14% when it was three times richer. Before the US stock market, China Stock Exchange fell by about 3% and Pinduoduo fell by about 1%. Broadcom rose by about 14%, the company's Q4 profit exceeded expectations, and AI revenue in the whole fiscal year doubled by 220%.The net purchase of southbound funds exceeded 10 billion yuan.
Yiling Pharmaceutical Co., Ltd.: The application for clinical trial of Lianhua Yuping Granule was approved, and Yiling Pharmaceutical announced that Beijing Yiling, a wholly-owned subsidiary, received the Notice of Approval for Clinical Trial of Drugs approved and issued by National Medical Products Administration on December 12, 2024, and agreed to carry out clinical trial of Lianhua Yuping Granule for qi deficiency syndrome of common cold.Bank of Communications: Wang Wenjin resigned as business director. Due to job transfer, Wang Wenjin has submitted a written report to the board of directors of the company and resigned as business director (corporate and institutional business). His resignation will take effect on December 13, 2024.The CSRC approved the registration application of Jiangnan New Materials Technology Co., Ltd. for initial public offering of shares.
The U.S. House of Representatives passed a bill to expand the judiciary.Twenty-five pilot banks in Shenzhen have opened a total of 64,000 cross-border wealth management accounts. The reporter was informed that by the end of November 2024, 25 pilot banks in Shenzhen had opened a total of 64,000 cross-border wealth management accounts, with a total amount of cross-border receipts and payments of 42.74 billion yuan, accounting for 48.1% and 44.2% of Guangdong-Hong Kong-Macao Greater Bay Area respectively.Iran has agreed to the IAEA's additional supervision of the Foldo uranium enrichment plant. In a report, the International Atomic Energy Agency (IAEA) said that Iran has agreed to the United Nations nuclear watchdog to take additional supervision measures on its Foldo uranium enrichment plant, after Iran indicated that it plans to significantly increase the production of highly enriched uranium at the plant. The IAEA said last week that Iran has transformed its Fordo uranium enrichment plant, located south of Tehran, which will "significantly increase the production speed of uranium with an abundance of 60%", which is close to 90% needed to make nuclear weapons. The International Atomic Energy Agency called on Iran to carry out inspections urgently, while European powers urged Tehran to "immediately stop its nuclear upgrade".
Strategy guide 12-14
Strategy guide 12-14
Strategy guide
12-14
Strategy guide 12-14
Strategy guide 12-14